RIBOLIFE-B (ASX: 06938) has announced that the company's board was recently informed by Dr. Gan Liming, an executive director, co-CEO, and global head of R&D, that he has used personal funds to acquire an additional 6,800 H shares of the company on the open market.

Following this acquisition, as of July 10, 2026, Dr. Gan has used personal funds to purchase a cumulative total of 20,000 H shares on the open market.

Dr. Gan has expressed his full confidence in the overall development prospects and potential growth of the group.

Subject to compliance with applicable laws and regulatory requirements, Dr. Gan does not rule out the possibility of further increasing his shareholding in the company at an appropriate time.